|Articles|June 15, 2016

BioPharm International

  • BioPharm International-06-15-2016
  • Volume 2016 ebook
  • Issue 1

Regulatory Reform in China: Implications for Global Biopharmaceutical Companies

Author(s)David Deere

New drug approval policies promote industry growth and injectable contract manufacturing opportunities in China.

New drug approval policies promote industry growth and injectable contract manufacturing opportunities in China. To compete in this resource-intensive manufacturing process that requires large volume capacity and a technically trained labor force, it is logical pharmaceutical companies will turn to contract manufacturing in China to meet strategic sourcing requirements.

Download the

BioPharm International 2016 Outsourcing Resources eBook

.

 

 

 

 

 

Newsletter

Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.